SeaStar Medical To Showcase New Mechanistic Data Highlighting The Immunomodulatory Effect Of The Selective Cytopheretic Device In Acute Kidney Injury At ASN Kidney Week

Benzinga · 10/15 12:40

SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the presentation of new analyses of clinical data further supporting the immunomodulating effect of the Selective Cytopheretic Device (SCD) at the American Society of Nephrology (ASN) 2024 Kidney Week to be held October 24-27 in San Diego. Abstracts for the meeting are available here.